Department of Cancer Immunology, Genentech, South San Francisco, CA.
Department of Cancer Immunology, Genentech, South San Francisco, CA
J Exp Med. 2018 Mar 5;215(3):985-997. doi: 10.1084/jem.20171626. Epub 2018 Feb 7.
CRISPR (clustered, regularly interspaced, short palindromic repeats)/Cas9 (CRISPR-associated protein 9) has become the tool of choice for generating gene knockouts across a variety of species. The ability for efficient gene editing in primary T cells not only represents a valuable research tool to study gene function but also holds great promise for T cell-based immunotherapies, such as next-generation chimeric antigen receptor (CAR) T cells. Previous attempts to apply CRIPSR/Cas9 for gene editing in primary T cells have resulted in highly variable knockout efficiency and required T cell receptor (TCR) stimulation, thus largely precluding the study of genes involved in T cell activation or differentiation. Here, we describe an optimized approach for Cas9/RNP transfection of primary mouse and human T cells without TCR stimulation that results in near complete loss of target gene expression at the population level, mitigating the need for selection. We believe that this method will greatly extend the feasibly of target gene discovery and validation in primary T cells and simplify the gene editing process for next-generation immunotherapies.
CRISPR(成簇、规律间隔、短回文重复)/Cas9(CRISPR 相关蛋白 9)已成为在多种物种中产生基因敲除的首选工具。在原代 T 细胞中进行高效基因编辑的能力不仅代表了研究基因功能的有价值的研究工具,而且也为基于 T 细胞的免疫疗法(如新一代嵌合抗原受体(CAR)T 细胞)带来了巨大的希望。先前尝试将 CRISPR/Cas9 应用于原代 T 细胞中的基因编辑,其基因敲除效率变化较大且需要 T 细胞受体(TCR)刺激,因此在很大程度上排除了研究参与 T 细胞激活或分化的基因的可能性。在这里,我们描述了一种优化的 Cas9/RNP 转染原代小鼠和人 T 细胞的方法,无需 TCR 刺激,从而导致目标基因表达在群体水平上几乎完全丧失,减轻了选择的需要。我们相信,这种方法将极大地扩展在原代 T 细胞中发现和验证靶基因的可行性,并简化下一代免疫疗法的基因编辑过程。